Exploratory composite endpoint demonstrates benefit of trilaciclib across multiple clinically meaningful components of myeloprotection in patients with small cell lung cancer-Reference-Cited by-同舟云学术

Exploratory composite endpoint demonstrates benefit of trilaciclib across multiple clinically meaningful components of myeloprotection in patients with small cell lung cancer

Published:2021-07-10 Issue: Volume: Page:
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Dómine Gómez Manuel¹,Csőszi Tibor²,Jaal Jana³,Kudaba Iveta⁴,Nikolov Krasimir⁵,Radosavljevic Davorin⁶,Xiao Jie⁷,Horton Janet K.⁷,Malik Rajesh K.⁷,Subramanian Janakiraman⁸

Affiliation:

1. Medical Oncology Department Hospital Universitario Fundación Jimenez Diaz Madrid Spain

2. County Oncology Centre Hetenyi Geza Korhaz Szolnok Hungary

3. Institute of Clinical Medicine, Department of Hematology and Oncology University of Tartu Tartu Estonia

4. Chemotherapy and Haematology Clinic Riga East Clinical University‐Latvian Oncology Center Riga Latvia

5. Department of Medical Oncology Complex Oncology Center Burgas Bulgaria

6. Clinic for Medical Oncology Institute for Oncology and Radiology of Serbia Belgrade Serbia

7. Clinical Development G1 Therapeutics, Inc. Research Triangle Park North Carolina USA

8. Division of Oncology, Saint Luke's Cancer Institute University of Missouri Kansas City Missouri USA

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.33705

Reference54 articles.

1. Current Diagnosis and Management of Small-Cell Lung Cancer

2. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

3. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

4. SEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC) (2019)

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Big Decisions on Small Cell Lung Cancer: A Focus on Clinical Care Updates and Patient Perspectives;American Society of Clinical Oncology Educational Book;2024-06

2. Trilaciclib dosage in Chinese patients with extensive-stage small cell lung cancer: a pooled pharmacometrics analysis;Acta Pharmacologica Sinica;2024-05-17

3. Trilaciclib: A Novel Approach to Mitigate Chemotherapy-Induced Myelosuppression in Cancer Treatment;Indian Journal of Medical and Paediatric Oncology;2024-04-30

4. Systemic Therapy for Small-Cell Lung Cancer: ASCO-Ontario Health (Cancer Care Ontario) Guideline;Journal of Clinical Oncology;2023-12-10

5. Quinazolinone derivatives as new potential CDK4/6 inhibitors, apoptosis inducers and radiosensitizers for breast cancer;Future Medicinal Chemistry;2023-07